Highlights T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Delayed Nasdaq Other stock markets 02:34:44 2024-04-29 pm EDT			5-day change	1st Jan Change
2.91 ^USD	+2.46%		-7.91%	-53.63%

05:09pm	Canaccord Genuity Adjusts Price Target on T2 Biosystems to $3 From $12, Maintains Hold Rating	MT
Apr. 23	Top Premarket Decliners	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	Mar. 28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	Mar. 20	CI
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	Mar. 20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	Mar. 18	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	Feb. 15	CI
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel	Feb. 12	DJ
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel	Feb. 12	CI
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group Pilot Study for Pneumonia Patients	Jan. 18	CI
T2 Biosystems, Inc. Announces FDA 510(K) Submission to Expand Use of the FDA-Cleared T2candida Panel to Include Pediatric Testing	Jan. 03	CI
T2 Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference	23-10-24	CI
T2 Biosystems Submits 510(k) to Add Detection of Acinetobacter Baumannii to List of Pathogens Covered by T2Bacteria Panel	23-10-12	MT
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel	23-09-19	CI
T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023	23-08-11	CI
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q2 Revenue $2M, vs. Street Est of $2M	23-08-07	MT
T2 Biosystems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
T2 Biosystems Seeks Acquisitions	23-08-06	CI
T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test	23-07-20	CI
T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023	23-07-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Highlights

Filters